Study guide

6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management

Singapore Nursing Board SNB

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Legal Framework & Regulatory Governing of Nursing in Singapore

1.1 Nurses and Midwives Act & SNB Regulatory Powers 1.2 Scope of Professional Nursing Practice & Accountability 1.3 Informed Consent, Confidentiality & PDPA in Healthcare

2 Chapter 2: Ethical Standards & Professional Code of Conduct

2.1 SNB Code for Nurses and Midwives & Ethical Principles 2.2 Patient Rights, Advocacy & End-of-Life Ethical Decision-Making 2.3 Safeguarding Vulnerable Patients & Mandatory Reporting

3 Chapter 3: Holistic Patient Assessment & Nursing Process

3.1 Comprehensive Physical Assessment & Vital Signs Monitoring 3.2 Early Warning Scores & Recognising the Deteriorating Patient 3.3 Nursing Diagnosis, Person-Centred Care Planning & Evaluation

4 Chapter 4: Communication, Documentation & Clinical Safety

4.1 Therapeutic Communication & Interpersonal Care Relationships 4.2 Clinical Documentation Standards & ISBAR Clinical Handover 4.3 Clinical Risk Management, Fall Prevention & Patient Safety Goals

5 Chapter 5: Infection Prevention & Control Standards

5.1 Standard & Transmission-Based Precautions (Infection Control) 5.2 Aseptic Technique, Surgical Hand Antisepsis & Wound Care Asepsis 5.3 Outbreak Management, Multi-Drug Resistant Organisms (MDROs) & Bio-waste

6 Chapter 6: Safe Medication Administration & Clinical Pharmacology

6.1 Rights of Medication Administration & High-Alert Medications 6.2 Dosage Calculations, Unit Conversions & Pediatric/Geriatric Adjustments 6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management 6.4 Medication Reconciliation, Storage & Controlled Substances Act in SG

7 Chapter 7: Intravenous Therapy, Fluid & Electrolyte Management

7.1 Fluid Balance, Electrolyte Disturbances & ABG Interpretation 7.2 Peripheral & Central Venous Line Access, Care & Complications 7.3 Blood Product Transfusion Standards, Safety & Adverse Reaction Management

8 Chapter 8: Respiratory Care & Oxygenation Management

8.1 Airway Management, Oxygen Therapy & Pulse Oximetry 8.2 Tracheostomy Care, Suctioning & Mechanical Ventilation Nursing 8.3 Nursing Care in Acute Respiratory Distress & Chronic Obstructive Pulmonary Disease

9 Chapter 9: Cardiovascular Nursing & Hemodynamic Monitoring

9.1 Cardiac Assessment, ECG Interpretation & Common Arrhythmias 9.2 Acute Coronary Syndrome, Heart Failure & Hypertensive Crises Nursing 9.3 Shock Classification, Fluid Resuscitation & Hemodynamic Monitoring

10 Chapter 10: Medical-Surgical Nursing: Gastrointestinal & Renal Systems

10.1 Enteral & Parenteral Nutrition Management 10.2 Care of Acute Abdomen, Ostomy Care & Gastrointestinal Bleeding 10.3 Acute Kidney Injury, Chronic Kidney Disease & Dialysis Nursing

11 Chapter 11: Endocrine & Metabolic Nursing Management

11.1 Diabetes Mellitus: Glycemic Control, Insulin Therapy & Complications 11.2 Management of Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.3 Thyroid, Adrenal & Pituitary Endocrine Disorders

12 Chapter 12: Neurological Nursing & Musculoskeletal Care

12.1 Neurological Assessment, Glasgow Coma Scale (GCS) & Stroke Care 12.2 Increased Intracranial Pressure (ICP) & Seizure Management 12.3 Musculoskeletal Assessment, Traction, Cast Care & Mobility Promotion

13 Chapter 13: Perioperative & Wound Management

13.1 Preoperative Assessment, Preparation & Informed Consent Verification 13.2 Intraoperative Standards, Surgical Time-Out & Anesthesia Monitoring 13.3 Postoperative Recovery, Pain Management & Wound Healing Staging

14 Chapter 14: Elder Care, Gerontological Nursing & Chronic Disease

14.1 Comprehensive Geriatric Assessment & Frailty Syndromes 14.2 Dementia, Delirium & Depression in Older Adults 14.3 Pressure Injury Prevention, Staging & Advanced Wound Dressings

15 Chapter 15: Mental Health Nursing & Psychosocial Care

15.1 Mental Health Assessment & Therapeutic Nurse-Patient Engagement 15.2 Mood Disorders, Psychosis & Crisis Intervention 15.3 Mental Health Act in Singapore, De-escalation & Patient Safety

16 Chapter 16: Palliative Care & Symptom Management

16.1 Principles of Palliative & End-of-Life Nursing Care 16.2 Pain Assessment, Opioid Titration & Breakthrough Pain Management 16.3 Advance Care Planning (ACP) & Care of the Dying Patient

17 Chapter 17: Interprofessional Collaboration & Care Coordination

17.1 Transdisciplinary Team Dynamics & Multidisciplinary Case Conferences 17.2 Care Coordination, Community Discharge Planning & Continuity of Care 17.3 Conflict Resolution & Interprofessional Communication

18 Chapter 18: Delegation, Supervision & Clinical Leadership

18.1 Principles of Delegation to Enrolled Nurses (ENs) & Ancillary Staff 18.2 Clinical Supervision, Resource Management & Ward Operations 18.3 Quality Improvement, Clinical Audit & Incident Reporting

19 Chapter 19: Evidence-Based Practice, Education & Professional Growth

19.1 Reflective Practice & SNB CPE (Continuing Professional Education) Requirements 19.2 Integrating Evidence-Based Practice (EBP) into Clinical Care 19.3 Clinical Education, Student Preceptorship & Mentorship

6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management

Key Takeaways Explain This Topic AI

Pharmacokinetics describes drug movement through Absorption, Distribution, Metabolism, and Excretion (ADME), governing serum drug concentrations and half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ).

Therapeutic Drug Monitoring (TDM) is essential for narrow therapeutic index drugs (e.g., Gentamicin, Vancomycin, Digoxin, Lithium, Phenytoin) to maintain serum levels within narrow safety windows.

Adverse Drug Reactions (ADRs) are categorized into Type A (augmented, dose-dependent, predictable) and Type B (bizarre, idiosyncratic/allergic, dose-independent), requiring mandatory reporting to the Health Sciences Authority (HSA) via PRISM.

In Singapore, pharmacogenomic screening for the HLA-B*1502 allele is mandatory prior to initiating Carbamazepine in Han Chinese, Malay, and Asian populations to prevent Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS).

Acute poisoning management follows the ABCDE stabilization approach combined with activated charcoal decontamination and targeted antidotes (e.g., N-acetylcysteine for paracetamol, Naloxone for opioids).

Last updated: July 2026

6.3 Pharmacokinetics, Adverse Drug Reactions & Poison Management

Clinical pharmacology forms the bedrock of safe medication administration. Understanding how the body processes drugs ( pharmacokinetics ) and how drugs affect the body ( pharmacodynamics ) enables registered nurses to monitor therapeutic efficacy, identify adverse drug reactions (ADRs), interpret drug blood levels, and execute emergency toxicology management under Health Sciences Authority (HSA) guidelines.

Pharmacokinetic Principles: The ADME Profile

Pharmacokinetics governs the time course of drug absorption, distribution, metabolism, and excretion: +--------------------------------------------------------------------------+

  • | THE ADME PHARMACOKINETIC CYCLE |
  • +--------------------------------------------------------------------------+
  • | 1. ABSORPTION : Route, bioavailability (F), gastric pH & emptying |
  • | 2. DISTRIBUTION : Protein binding (albumin), Vd, blood-brain barrier |
  • | 3. METABOLISM : Hepatic CYP450 enzymes (inducers vs inhibitors) |
  • | 4. EXCRETION : Renal filtration/secretion, biliary, half-life (t1/2) |
  • +--------------------------------------------------------------------------+

Key Concepts:

Bioavailability ( F F F ) : The fraction of administered active drug reaching systemic circulation intact ( 100 % 100\% 100% for IV formulations; lower for oral due to first-pass hepatic metabolism ).

Volume of Distribution ( V d V_d V d ​ ) : The theoretical fluid volume required to contain the total drug mass at systemic plasma concentration.

Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ​ ) : The time required for plasma drug concentration to decline by 50 % 50\% 50% . Steady-state concentration is typically achieved after 4 to 5 half-lives 4 \text{ to } 5 \text{ half-lives} 4 to 5 half-lives of continuous or scheduled dosing.

Cytochrome P450 System : Hepatic enzymes responsible for metabolizing most drugs.

CYP Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin): Accelerate drug metabolism, reducing therapeutic levels of co-administered drugs.

CYP Inhibitors (e.g., Ketoconazole, Erythromycin, Grapefruit Juice, Cimetidine): Suppress metabolism, causing drug accumulation and toxicity.

Therapeutic Drug Monitoring (TDM) for Narrow Therapeutic Index Drugs

Drugs with a Narrow Therapeutic Index (NTI) have a small margin between therapeutic efficacy and lethal toxicity. Nurses must coordinate precise blood sampling times for TDM:

Drug Name Target Therapeutic Range TDM Sampling Standard Toxicity Clinical Manifestations

Gentamicin / Amikacin Peak : 5 – 10 mcg/mL 5\text{--}10\text{ mcg/mL} 5 – 10 mcg/mL ; Trough : < 2 mcg/mL < 2\text{ mcg/mL} < 2 mcg/mL Peak : 30 min post IV infusion.; Trough : Within 30 min prior to next dose. Nephrotoxicity (elevated creatinine), Ototoxicity (tinnitus, vestibular balance loss, irreversible deafness).

Vancomycin Trough : 15 – 20 mcg/mL 15\text{--}20\text{ mcg/mL} 15 – 20 mcg/mL (severe infection/MRSA) Draw trough level within 30 min immediately prior to 4th or 5th dose. Red Man Syndrome (rapid infusion histamine release; flush, hypotension), Nephrotoxicity.

Digoxin Range : 0.5 – 2.0 ng/mL 0.5\text{--}2.0\text{ ng/mL} 0.5 – 2.0 ng/mL Draw sample at least 6--8 hours post-dose (ideally trough). Anorexia, nausea, yellow-green visual halos, severe bradycardia, ventricular arrhythmias.

Phenytoin Range : 10 – 20 mcg/mL 10\text{--}20\text{ mcg/mL} 10 – 20 mcg/mL Trough level prior to next dose. Note non-linear saturation kinetics. Nystagmus, ataxia, gingival hyperplasia, confusion, peripheral neuropathy.

Lithium Range : 0.6 – 1.2 mEq/L 0.6\text{--}1.2\text{ mEq/L} 0.6 – 1.2 mEq/L 12 hours post evening dose (trough). Fine hand tremor, polyuria, hypothyroidism, coarse tremor, seizures, coma.

Adverse Drug Reactions (ADRs) & HSA Pharmacovigilance

In Singapore, the Health Sciences Authority (HSA) oversees national pharmacovigilance. RNs are legally and professionally required to identify and report ADRs.

Classification of ADRs:

Type A (Augmented / Predictable) : Dose-dependent extensions of pharmacological action (e.g., hypoglycemia from insulin, bleeding from warfarin, bradycardia from beta-blockers). Management involves dose reduction.

Type B (Bizarre / Unpredictable) : Idiosyncratic or immunological reactions independent of dose (e.g., anaphylaxis from penicillin, SJS/TEN from allopurinol). Management mandates immediate drug discontinuation and lifelong allergy flagging.

Pharmacogenomic Safety: HLA-B*1502 Screening in Singapore

Singapore's multi-ethnic demographic presents specific genetic risks. HSA safety alerts mandate genetic testing for the HLA-B*1502 allele prior to starting Carbamazepine in Han Chinese, Malay, and Asian patients. Carrying HLA-B*1502 dramatically increases the risk of life-threatening Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) .

Acute Poison Management & Antidote Therapy

When managing acute drug overdose or chemical ingestion, the nurse follows the structured ABCDE emergency algorithm:

Airway, Breathing, Circulation : Secure patent airway, provide supplemental O 2 O_2 O 2 ​ , establish IV access.

Decontamination : Activated Charcoal ( 1 g/kg 1\text{ g/kg} 1 g/kg PO/NGT) is most effective within 1 hour of oral toxin ingestion. Contraindicated in corrosive (acid/alkali) ingestion, petroleum distillates, heavy metals (lithium, iron), or impaired airway without intubation.

Key Clinical Antidotes:

Toxic Agent / Overdose First-Line Antidote Mechanism / Clinical Key Points

Paracetamol (Acetaminophen) N-Acetylcysteine (NAC) Replenishes hepatic glutathione stores. Administer within 8 hours of ingestion based on Rumack-Matthew nomogram.

Opioids (Morphine, Fentanyl) Naloxone Competitive μ \mu μ -opioid receptor antagonist. Monitor for resedation as Naloxone half-life ( 30 – 90 min 30\text{--}90\text{ min} 30 – 90 min ) is shorter than morphine.

Benzodiazepines Flumazenil Competitive GABA receptor antagonist. Caution: can precipitate lethal withdrawal seizures in chronic users or co-ingestions.

Organophosphates / Pesticides Atropine + Pralidoxime (2-PAM) Atropine blocks muscarinic cholinergic excess (salivation, bronchospasm, bradycardia); Pralidoxime reactivates acetylcholinesterase.

Digoxin Toxicity Digoxin Immune Fab (Digibind) Antigen-binding Fab fragments bind free digoxin for renal elimination.

Beta-Blockers / CCBs Glucagon / High-Dose Insulin Glucagon increases intracellular cAMP; High-Dose Insulin Euglycemic Therapy (HIET) restores myocardial energy metabolism.

Loading diagram... Pharmacokinetic Serum Drug Concentration Curve & Therapeutic Window